Spondyloarthritis and Sarcopenia: Prevalence of Probable Sarcopenia and its Impact on Disease Burden: The Saspar Study.
Muscle mass
Muscle strength
Probable sarcopenia
SarQoL®
Sarcopenia
Spondyloarthritis
Journal
Calcified tissue international
ISSN: 1432-0827
Titre abrégé: Calcif Tissue Int
Pays: United States
ID NLM: 7905481
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
14
11
2022
accepted:
23
02
2023
medline:
22
5
2023
pubmed:
23
3
2023
entrez:
22
3
2023
Statut:
ppublish
Résumé
To evaluate the prevalence of probable, confirmed, and severe sarcopenia in spondyloarthritis (SpA), according to the European Working Group on Sarcopenia in Older People 2019 (EWGSOP2) definition. A total of 103 patients (51% women) with SpA, mean age 47.1 ± 13.7 years, were included and compared to 103 age- and sex-matched controls. Grip strength was measured by dynamometry. Body composition was assessed by whole-body densitometry. In SpA patients gait speed was measured by the 4-m-distance walk test and quality of life was evaluated with a specific health-related questionnaire for sarcopenia (SaRQoL®). Twenty-two SpA patients (21%) versus 7 controls (7%) had a low grip strength, i.e., probable sarcopenia (p < 0.01), 15 SpA (15%) patients and 7 controls (7%) had low Skeletal Muscle mass Index (SMI) (ns), respectively, and 5 and 2% of SpA patients and controls had low grip strength and low SMI, i.e., confirmed sarcopenia (ns). All the sarcopenic SpA patients had a low gait speed, i.e., severe sarcopenia. Finally, probable sarcopenic SpA patients had significantly higher C-Reactive Protein (CRP, p < 0.001) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI score, p < 0.01), lower gait speed (p < 0.001), and SarQoL® score (p < 0.001) than SpA patients with normal grip strength. According to EWGSOP2 definition, the prevalence of probable sarcopenia was significantly higher in SpA patients compared to controls. Probable sarcopenia was associated with higher inflammation and disease activity, impaired muscle performance, and quality of life. These results suggest that muscle strength may be a salient hallmark in SpA.
Identifiants
pubmed: 36944706
doi: 10.1007/s00223-023-01074-3
pii: 10.1007/s00223-023-01074-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
647-655Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR et al (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147(8):755–763
pubmed: 9554417
doi: 10.1093/oxfordjournals.aje.a009520
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F et al (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European working group on Sarcopenia in older people. Age Ageing 39(4):412–423
pubmed: 20392703
pmcid: 2886201
doi: 10.1093/ageing/afq034
Tournadre A, Vial G, Capel F, Soubrier M, Boirie Y (2019) Sarcopenia. Joint Bone Spine 86(3):309–314
pubmed: 30098424
doi: 10.1016/j.jbspin.2018.08.001
An HJ, Tizaoui K, Terrazzino S, Cargnin S, Lee KH, Nam SW et al (2020) Sarcopenia in autoimmune and rheumatic diseases: a comprehensive review. Int J Mol Sci 21(16):5678
pubmed: 32784808
pmcid: 7461030
doi: 10.3390/ijms21165678
Bhasin S, Travison TG, Manini TM, Patel S, Pencina KM, Fielding RA et al (2020) Sarcopenia definition: the position statements of the Sarcopenia definition and outcomes consortium. J Am Geriatr Soc 68(7):1410–1418
pubmed: 32150289
doi: 10.1111/jgs.16372
Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G et al (2010) Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics.” Clin Nutr 29(2):154–159
pubmed: 20060626
doi: 10.1016/j.clnu.2009.12.004
Cao L, Morley JE (2016) Sarcopenia is recognized as an independent condition by an international classification of disease, tenth revision, clinical modification (ICD-10-CM) code. J Am Med Dir Assoc 17(8):675–677
pubmed: 27470918
doi: 10.1016/j.jamda.2016.06.001
Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16–31
pubmed: 30312372
doi: 10.1093/ageing/afy169
Saraux A, Guillemin F, Guggenbuhl P, Roux CH, Fardellone P, Le Bihan E et al (2005) Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis 64(10):1431–1435
pubmed: 15817661
pmcid: 1755229
doi: 10.1136/ard.2004.029207
Valido A, Crespo CL, Pimentel-Santos FM (2019) Muscle evaluation in axial spondyloarthritis-the evidence for Sarcopenia. Front Med (Lausanne) 6:219
pubmed: 31681777
doi: 10.3389/fmed.2019.00219
Aguiar R, Sequeira J, Meirinhos T, Ambrosio C, Barcelos A (2014) SARCOSPA - Sarcopenia in spondyloarthritis patients. Acta Reumatol Port 39(4):322–326
pubmed: 25584619
El Maghraoui A, Ebo’o FB, Sadni S, Majjad A, Hamza T, Mounach A (2016) Is there a relation between pre-sarcopenia, sarcopenia, cachexia and osteoporosis in patients with ankylosing spondylitis? BMC Musculoskelet Disord 17:268
pubmed: 27401188
pmcid: 4940725
doi: 10.1186/s12891-016-1155-z
Barone M, Viggiani MT, Anelli MG, Fanizzi R, Lorusso O, Lopalco G et al (2018) Sarcopenia in patients with rheumatic diseases: prevalence and associated risk factors. J Clin Med. 7(12):504
pubmed: 30513782
pmcid: 6306844
doi: 10.3390/jcm7120504
Krajewska-Wlodarczyk M, Owczarczyk-Saczonek A, Placek W (2017) Changes in body composition and bone mineral density in postmenopausal women with psoriatic arthritis. Reumatologia 55(5):215–221
pubmed: 29332959
pmcid: 5746631
doi: 10.5114/reum.2017.71627
Sornay-Rendu E, Boutroy S, Munoz F, Delmas PD (2007) Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study. J Bone Miner Res 22(3):425–433
pubmed: 17181395
doi: 10.1359/jbmr.061206
Nagy H, Sornay-Rendu E, Boutroy S, Vilayphiou N, Szulc P, Chapurlat R (2013) Impaired trabecular and cortical microarchitecture in daughters of women with osteoporotic fracture: the MODAM study. Osteoporos Int 24(6):1881–1889
pubmed: 23179577
doi: 10.1007/s00198-012-2223-3
Chaitou A, Boutroy S, Vilayphiou N, Munoz F, Delmas PD, Chapurlat R et al (2010) Association between bone turnover rate and bone microarchitecture in men: the STRAMBO study. J Bone Miner Res 25(11):2313–2323
pubmed: 20499368
doi: 10.1002/jbmr.124
Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C et al (2011) A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing 40(4):423–429
pubmed: 21624928
doi: 10.1093/ageing/afr051
Neumann S, Kwisda S, Krettek C, Gaulke R (2017) Comparison of the grip strength using the martin-vigorimeter and the JAMAR-dynamometer: establishment of normal values. In Vivo 31(5):917–924
pubmed: 28882959
pmcid: 5656866
Andreoli A, Scalzo G, Masala S, Tarantino U, Guglielmi G (2009) Body composition assessment by dual-energy X-ray absorptiometry (DXA). Radiol Med 114(2):286–300
pubmed: 19266259
doi: 10.1007/s11547-009-0369-7
Beaudart C, Biver E, Reginster JY, Rizzoli R, Rolland Y, Bautmans I et al (2015) Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. Age Ageing 44(6):960–966
pubmed: 26433796
pmcid: 4621234
doi: 10.1093/ageing/afv133
Marcora S, Casanova F, Williams E, Jones J, Elamanchi R, Lemmey A (2006) Preliminary evidence for cachexia in patients with well-established ankylosing spondylitis. Rheumatology (Oxford) 45(11):1385–1388
pubmed: 16603581
doi: 10.1093/rheumatology/kel127
Beenakker KG, Ling CH, Meskers CG, de Craen AJ, Stijnen T, Westendorp RG et al (2010) Patterns of muscle strength loss with age in the general population and patients with a chronic inflammatory state. Ageing Res Rev 9(4):431–436
pubmed: 20553969
pmcid: 7105185
doi: 10.1016/j.arr.2010.05.005
Kim SC, Lee YG, Park SB, Kim TH, Lee KH (2017) Muscle mass, strength, mobility, quality of life, and disease severity in ankylosing spondylitis patients: a preliminary study. Ann Rehabil Med 41(6):990–997
pubmed: 29354575
pmcid: 5773442
doi: 10.5535/arm.2017.41.6.990
Dos Santos FP, Constantin A, Laroche M, Destombes F, Bernard J, Mazieres B et al (2001) Whole body and regional bone mineral density in ankylosing spondylitis. J Rheumatol 28(3):547–549
pubmed: 11296956
Toussirot E, Michel F, Wendling D (2001) Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. Rheumatology (Oxford) 40(8):882–888
pubmed: 11511757
doi: 10.1093/rheumatology/40.8.882
Ben Tekaya A, Mehmli T, Ben Sassi M, Teyeb Z, Bouden S, Rouached L et al (2022) Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. https://doi.org/10.1007/s10067-022-06454-y
doi: 10.1007/s10067-022-06454-y
pubmed: 36462127
Reiss J, Iglseder B, Alzner R, Mayr-Pirker B, Pirich C, Kassmann H et al (2019) Consequences of applying the new EWGSOP2 guideline instead of the former EWGSOP guideline for sarcopenia case finding in older patients. Age Ageing 48(5):719–724
pubmed: 31112221
doi: 10.1093/ageing/afz035
Locquet M, Beaudart C, Petermans J, Reginster JY, Bruyere O (2019) EWGSOP2 versus EWGSOP1: impact on the prevalence of sarcopenia and its major health consequences. J Am Med Dir Assoc 20(3):384–385
pubmed: 30661861
doi: 10.1016/j.jamda.2018.11.027
Yang L, Yao X, Shen J, Sun G, Sun Q, Tian X et al (2020) Comparison of revised EWGSOP criteria and four other diagnostic criteria of sarcopenia in Chinese community-dwelling elderly residents. Exp Gerontol 130:110798
pubmed: 31816424
doi: 10.1016/j.exger.2019.110798
Warzecha M, Amarowicz J, Berwecka M, Czerwinski E, Kumorek A (2020) Relation between risk of falls, sarcopenia and parameters assessing quality of skeletal muscles in a group of postmenopausal women. Menopause Rev 19(3):123–129
doi: 10.5114/pm.2020.99617
Wallengren O, Bosaeus I, Frandin K, Lissner L, Falk Erhag H, Wetterberg H et al (2021) Comparison of the 2010 and 2019 diagnostic criteria for sarcopenia by the European Working Group on Sarcopenia in Older People (EWGSOP) in two cohorts of Swedish older adults. BMC Geriatr 21(1):600
pubmed: 34702174
pmcid: 8547086
doi: 10.1186/s12877-021-02533-y
Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE (2018) Gender differences in axial spondyloarthritis: women are not so lucky. Curr Rheumatol Rep 20(6):35
pubmed: 29754330
pmcid: 5949138
doi: 10.1007/s11926-018-0744-2
Maas F, Arends S, van der Veer E, Wink F, Efde M, Bootsma H et al (2016) Obesity is common in axial spondyloarthritis and is associated with poor clinical outcome. J Rheumatol 43(2):383–387
pubmed: 26669924
doi: 10.3899/jrheum.150648
Ibanez Vodnizza S, Visman IM, van Denderen C, Lems WF, Jaime F, Nurmohamed MT et al (2017) Muscle wasting in male TNF-alpha blocker naive ankylosing spondylitis patients: a comparison of gender differences in body composition. Rheumatology (Oxford) 56(9):1566–1572
pubmed: 28605535
doi: 10.1093/rheumatology/kex187
Rusman T, van Bentum RE, van der Horst-Bruinsma IE (2020) Sex and gender differences in axial spondyloarthritis: myths and truths. Rheumatology (Oxford) 59(Supplement_4):38–46
doi: 10.1093/rheumatology/keaa543
Toussirot E (2020) The interrelations between biological and targeted synthetic agents used in inflammatory joint diseases, and obesity or body composition. Metabolites 10(3):107
pubmed: 32183053
pmcid: 7175105
doi: 10.3390/metabo10030107
Hmamouchi I, Roux C, Paternotte S, Kolta S, Dougados M, Briot K (2014) Early increase of abdominal adiposity in patients with spondyloarthritis receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 41(6):1112–1117
pubmed: 24737911
doi: 10.3899/jrheum.131150
Beaudart C, Reginster JY, Geerinck A, Locquet M, Bruyere O (2017) Current review of the SarQoL(R): a health-related quality of life questionnaire specific to sarcopenia. Expert Rev Pharmacoecon Outcomes Res 17(4):335–341
pubmed: 28749192
doi: 10.1080/14737167.2017.1360768
Witham MD, Heslop P, Dodds RM, Clegg AP, Hope SV, McDonald C et al (2022) Performance of the SarQoL quality of life tool in a UK population of older people with probable sarcopenia and implications for use in clinical trials: findings from the SarcNet registry. BMC Geriatr 22(1):368
pubmed: 35477354
pmcid: 9043890
doi: 10.1186/s12877-022-03077-5
Schaap LA, van Schoor NM, Lips P, Visser M (2018) Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: the longitudinal aging study Amsterdam. J Gerontol A Biol Sci Med Sci 73(9):1199–1204
pubmed: 29300839
doi: 10.1093/gerona/glx245
Scott D, Hayes A, Sanders KM, Aitken D, Ebeling PR, Jones G (2014) Operational definitions of sarcopenia and their associations with 5-year changes in falls risk in community-dwelling middle-aged and older adults. Osteoporos Int 25(1):187–193
pubmed: 23800748
doi: 10.1007/s00198-013-2431-5
Lopez-Medina C, Molto A, Sieper J, Duruoz T, Kiltz U, Elzorkany B et al (2021) Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. RMD Open 7(1):e001450
pubmed: 33462157
pmcid: 7816910
doi: 10.1136/rmdopen-2020-001450
Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A et al (2003) Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol 95(5):1851–60
pubmed: 14555665
doi: 10.1152/japplphysiol.00246.2003